Literature DB >> 23201134

Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions.

Agnieszka Maliszewska1, Luis J Leandro-Garcia, Esmeralda Castelblanco, Anna Macià, Aguirre de Cubas, Gonzalo Goméz-López, Lucía Inglada-Pérez, Cristina Álvarez-Escolá, Leticia De la Vega, Rocío Letón, Álvaro Gómez-Graña, Iñigo Landa, Alberto Cascón, Cristina Rodríguez-Antona, Salud Borrego, Mariangela Zane, Francesca Schiavi, Isabella Merante-Boschin, Maria R Pelizzo, David G Pisano, Giuseppe Opocher, Xavier Matias-Guiu, Mario Encinas, Mercedes Robledo.   

Abstract

Medullary thyroid carcinoma accounts for 2% to 5% of thyroid malignancies, of which 75% are sporadic and the remaining 25% are hereditary and related to multiple endocrine neoplasia type 2 syndrome. Despite a genotype-phenotype correlation with specific germline RET mutations, knowledge of pathways specifically associated with each mutation and with non-RET-mutated sporadic MTC remains lacking. Gene expression patterns have provided a tool for identifying molecular events related to specific tumor types and to different clinical features that could help identify novel therapeutic targets. Using transcriptional profiling of 49 frozen MTC specimens classified as RET mutation, we identified PROM1, LOXL2, GFRA1, and DKK4 as related to RET(M918T) and GAL as related to RET(634) mutation. An independent series of 19 frozen and 23 formalin-fixed, paraffin-embedded (FFPE) MTCs was used for validation by RT-qPCR. Two tissue microarrays containing 69 MTCs were available for IHC assays. According to pathway enrichment analysis and gene ontology biological processes, genes associated with the MTC(M918T) group were involved mainly in proliferative, cell adhesion, and general malignant metastatic effects and with Wnt, Notch, NFκB, JAK/Stat, and MAPK signaling pathways. Assays based on silencing of PROM1 by siRNAs performed in the MZ-CRC-1 cell line, harboring RET(M918T), caused an increase in apoptotic nuclei, suggesting that PROM1 is necessary for survival of these cells. This is the first report of PROM1 overexpression among primary tumors.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23201134     DOI: 10.1016/j.ajpath.2012.10.025

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  12 in total

1.  Quantitative Proteomics Analysis of Sporadic Medullary Thyroid Cancer Reveals FN1 as a Potential Novel Candidate Prognostic Biomarker.

Authors:  Shaohua Zhan; Jinming Li; Tianxiao Wang; Wei Ge
Journal:  Oncologist       Date:  2018-05-08

2.  Medullary thyroid carcinoma: a 25-year perspective.

Authors:  Xavier Matias-Guiu; Ronald De Lellis
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

3.  Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.

Authors:  Cinzia Puppin; Cosimo Durante; Marialuisa Sponziello; Antonella Verrienti; Valeria Pecce; Elisa Lavarone; Federica Baldan; Antonio Francesco Campese; Amelie Boichard; Ludovic Lacroix; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Endocrine       Date:  2014-02-26       Impact factor: 3.633

4.  Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma.

Authors:  Hai Song; Chuwen Lin; Erica Yao; Kuan Zhang; Xiaoling Li; Qingzhe Wu; Pao-Tien Chuang
Journal:  J Biol Chem       Date:  2017-01-24       Impact factor: 5.157

5.  Key genes and pathways predicted in papillary thyroid carcinoma based on bioinformatics analysis.

Authors:  J Yu; W Mai; Y Cui; L Kong
Journal:  J Endocrinol Invest       Date:  2016-06-01       Impact factor: 4.256

6.  Differences in the transcriptome of medullary thyroid cancer regarding the status and type of RET gene mutations.

Authors:  Malgorzata Oczko-Wojciechowska; Michal Swierniak; Jolanta Krajewska; Malgorzata Kowalska; Monika Kowal; Tomasz Stokowy; Bartosz Wojtas; Dagmara Rusinek; Agnieszka Pawlaczek; Agnieszka Czarniecka; Sylwia Szpak-Ulczok; Tomasz Gawlik; Ewa Chmielik; Tomasz Tyszkiewicz; Barbara Nikiel; Dariusz Lange; Michal Jarzab; Malgorzata Wiench; Barbara Jarzab
Journal:  Sci Rep       Date:  2017-02-09       Impact factor: 4.379

7.  MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.

Authors:  Alf Spitschak; Claudia Meier; Bhavani Kowtharapu; David Engelmann; Brigitte M Pützer
Journal:  Mol Cancer       Date:  2017-01-26       Impact factor: 27.401

Review 8.  Recent advances in the biology and therapy of medullary thyroid carcinoma.

Authors:  Barry Nelkin
Journal:  F1000Res       Date:  2017-12-28

Review 9.  Role of DKK4 in Tumorigenesis and Tumor Progression.

Authors:  Xinjia Cai; Zhigang Yao; Long Li; Junhui Huang
Journal:  Int J Biol Sci       Date:  2018-04-26       Impact factor: 6.580

Review 10.  Influencers on Thyroid Cancer Onset: Molecular Genetic Basis.

Authors:  Berta Luzón-Toro; Raquel María Fernández; Leticia Villalba-Benito; Ana Torroglosa; Guillermo Antiñolo; Salud Borrego
Journal:  Genes (Basel)       Date:  2019-11-08       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.